The European Medicines Agency (EMA) granted the qualification of “Small and Medium-Sized Enterprises” (SME) to Microviable Therapeutics. The European Medicines Agency (EMA) provides incentives and support for micro, small and medium-sized enterprises (SMEs) that are [...]
Marta has a degree in Biology (2014) and a Food Biotechnology Master (2016) at the University of Oviedo, plus a MS in Microbiota, Probiotics and Prebiotics at the European University at Madrid (2021) with MS [...]
Claudio Hidalgo Cantabrana, PhD, CEO at Microviable, and our CBO, Rafael M. Permuy, MBA, will be attending BIO-Europe event in Leipzig, Germany, from October 24th to 26th. BIO-Europe® is the preeminent partnering conference for the [...]
Welcome Pilar Manrique, PhD on board. Pilar obtained her undergraduate degree in Biotechnology at Universidad Francisco de Vitoria (2009) and her doctorate at Montana State University (2018). Pilar has worked over ten years studying the [...]
Microviable Therapeutics announces Research Collaboration with the University Medical Center Utrecht and Artizan Biosciences Inc.
Gijón, 21st July 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, announced a research agreement with the University Medical Center of Utrecht (The Netherlands) and Artizan Biosciences [...]
Microviable Therapeutics announces Research Collaboration with Venter Pharma and Inmunomet Intolerancia y Disbiosis
Gijón, July 7, 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, today announced that it has entered into a research contract with Venter Pharma SL. and Inmunomet [...]
Microviable Therapeutics welcomes Manuel Arenal on board. He has Master´s degree in Business Administration and Management at the University of Oviedo (MBA, 2015). He holds Master in Management at the ESC Clermont-Ferrand (2016) although he [...]
Microviable announces 1.5 million € investment to advance the company´s microbiota-derived biotherapeutic products.
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL. Microviable [...]
As part of our growth and consolidation as a microbiome company focused on therapeutics we have several openings to join our team! Are you ready to rock? Check out our careers section and submit [...]
Microviable Therapeutics SL (Gijón, Asturias, Spain), announced a contractual agreement with BCD Bioscience Inc. (California, USA) to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome. Microviable expertise on gut microbiome research [...]